Industrial Engineering Department, Universidad de Chile, Santiago, Chile.
Instituto Sistemas Complejos de Ingeniería, Santiago, Chile.
PLoS One. 2022 Nov 10;17(11):e0271929. doi: 10.1371/journal.pone.0271929. eCollection 2022.
Colorectal cancer (CRC) is the third most frequent malignant disease in the world. In some countries with established screening programs, its incidence and mortality have decreased, and survival has improved.
To obtain reliable data about the epidemiology of CRC in Chile, we analyzed the trends in the last ten years and the influence of observable factors on survival, including a nationwide health program for CRC treatment access (GES program).
Publicly available data published by the Ministry of Health and National Institute of Statistics were used. Data were obtained from registries of mortality and hospital discharges, making follow-up of the individuals possible. Crude and age-standardized incidence and mortality rates were calculated, and individual survival was studied by constructing Kaplan-Meier curves. Finally, a Cox statistical model was established to estimate the impact of the observable factors.
We found 37,217 newly identified CRC patients between 2008 and 2019 in Chile, corresponding to 103,239 hospital discharges. In the same period, 24,217 people died of CRC. A nearly linear, steady increase in crude incidence, mortality and prevalence was observed. CRC incidence was the lowest in the North of the country, increasing toward the South and reaching a maximum value of 34.6/100,000 inhabitants/year in terms of crude incidence and 20.7/100,000 inhabitants/year in terms of crude mortality in the XII region in 2018. We found that older patients had lower survival rates, as well as men compared to women. Survival was significantly better for patients with private insurance than those under the public insurance system, and the treating hospital also played a significant role in the survival of patients. Patients in the capital region survived longer than those in almost every other part of the country. We found no significant effect on survival associated with the GES program.
We found important inequalities in the survival probabilities for CRC patients in Chile. Survival depends mainly on the type of insurance, access to more complex hospitals, and geographical location; all three factors correlated with socioeconomic status of the population. Our work emphasized the need to create specific programs addressing primary causes to decrease the differences in CRC survival.
结直肠癌(CRC)是世界上第三大常见的恶性疾病。在一些建立了筛查计划的国家,其发病率和死亡率有所下降,生存率有所提高。
为了获得智利 CRC 流行病学的可靠数据,我们分析了过去十年的趋势以及可观察因素对生存率的影响,包括全国 CRC 治疗机会的健康计划(GES 计划)。
使用卫生部和国家统计局公布的公开数据。从死亡率和住院出院登记处获取数据,以便对个体进行随访。计算了粗发病率和标准化发病率及死亡率,并通过构建 Kaplan-Meier 曲线研究个体生存率。最后,建立 Cox 统计模型来估计可观察因素的影响。
我们在智利发现了 2008 年至 2019 年间 37217 例新确诊的 CRC 患者,对应 103239 例住院出院。同期,24217 人死于 CRC。我们观察到粗发病率、死亡率和患病率呈近乎线性的稳定增长。该国北部的 CRC 发病率最低,向南逐渐增加,2018 年在第十二区达到 34.6/100000 居民/年的最高粗发病率和 20.7/100000 居民/年的最高粗死亡率。我们发现,年龄较大的患者生存率较低,男性患者的生存率低于女性患者。与公共保险制度相比,私人保险患者的生存率显著提高,治疗医院在患者生存率方面也发挥了重要作用。首都地区的患者比该国其他地区的患者存活时间更长。我们发现 GES 计划对生存率没有显著影响。
我们发现智利 CRC 患者的生存率存在重要差异。生存率主要取决于保险类型、获得更复杂医院的机会以及地理位置;这三个因素都与人口的社会经济地位相关。我们的研究强调需要制定具体的方案来解决初级病因,以减少 CRC 生存率的差异。